NCT00706706已完成4 期
A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology that is not amenable to surgery.
- •Evidence of unidimensionally measurable disease
- •Male or female, 18 years of age or older.
- •ECOG performance status 0 or
- •Resolution of all acute toxic effects
- •Adequate organ function.
排除标准
- •Renal cell carcinoma without any clear (conventional) cell component.
- •Prior systemic therapy for metastatic disease of any kind of RCC, such as Interferon or Interleukin, chemotherapy, hormonal, investigational or targeted therapies. Patients may have received prior adjuvant therapy with Interferon and/or Interleukin if recurrence occurred > 6 months after adjuvant therapy completion.
- •Major surgery or radiation therapy <4 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated.
- •NCI CTCAE grade 3 hemorrhage <4 weeks of starting the study treatment.
- •Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer.
- •History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI scan.
- •Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, and 6 months for pulmonary embolism.
- •Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
- •Ongoing cardiac dysrhythmias, atrial fibrillation, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- •Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- •Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Current treatment on another clinical trial.
- •Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
研究组 & 干预措施
sunitinib
Experimental
single agent sunitinib, single arm
干预措施: Sunitinib Malate (SU011248) (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: Baseline, Day 28 of Cycles 1, 2, 3, 4 and even cycles thereafter until disease progression or every 2 months until death (up to 88 weeks)
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
次要结局
- Percentage of Participants With Objective Response (OR)(Baseline, Day 28 of Cycles 1, 2, 3, 4 and even cycles thereafter until disease progression or every 2 months until death (up to 88 weeks))
- Overall Survival (OS)(Baseline, Day 28 of Cycles 1, 2, 3, 4 and even cycles thereafter until disease progression or every 2 months until death (up to 88 weeks))
- One Year Survival Probability(Baseline, Day 28 of Cycles 1, 2, 3, 4 and even cycles thereafter, every 2 months until death (up to 1 year))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorGastrointestinal Neoplasms, Gastrointestinal Stromal TumorsNCT00793871Pfizer60
已完成
4 期
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsWell-differentiated Pancreatic Neuroendocrine TumorNCT01525550Pfizer106
已完成
1 期
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyAccelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Grade III Lymphomatoid GranulomatosisAdult Langerhans Cell HistiocytosisAdult Nasal Type Extranodal NK/T-cell LymphomaAggressive NK-cell LeukemiaAIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related MalignanciesAIDS-related Small Noncleaved Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Neutrophilic LeukemiaChronic Phase Chronic Myelogenous LeukemiaCutaneous B-cell Non-Hodgkin Lymphomade Novo Myelodysplastic SyndromesExtramedullary PlasmacytomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaHIV InfectionHIV-associated Hodgkin LymphomaIntraocular LymphomaIsolated Plasmacytoma of BoneLight Chain Deposition DiseaseMyelodysplastic Syndrome With Isolated Del(5q)Myelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyeloid/NK-cell Acute LeukemiaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaOsteolytic Lesions of Multiple MyelomaPeripheral T-cell LymphomaPlasma Cell NeoplasmMast Cell LeukemiaChronic Eosinophilic LeukemiaPreviously Treated Myelodysplastic SyndromesPrimary Systemic AmyloidosisProgressive Hairy Cell Leukemia, Initial TreatmentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaEssential ThrombocythemiaProlymphocytic LeukemiaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Renal Cell CancerRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRefractory Multiple MyelomaRelapsing Chronic Myelogenous LeukemiaStage IV Renal Cell CancerT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaUnspecified Adult Solid Tumor, Protocol SpecificWaldenström MacroglobulinemiaChronic Myelomonocytic LeukemiaPolycythemia VeraPrimary MyelofibrosisClear Cell Renal Cell CarcinomaPost-transplant Lymphoproliferative DisorderNCT00890747National Cancer Institute (NCI)42
进行中（未招募）
不适用
Study of Sunitinib in Young Patients With Refractory Solid TumoursEUCTR2012-000690-23-Outside-EU/EEAational Institution of Health (NCI)60
已完成
1 期
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal TumorsNCT00457743Pfizer36